
    
      After screening, each eligible patient will undergo a treatment of OBP-301 within 14 days and
      will automatically enter follow-up period.

      The follow-up period is up to 12 weeks after the last injection in the phase I part.

      Each patient will return for follow-up visit weekly in the first month after the last
      injection, and then every 4 weeks up to the end of follow-up period.
    
  